Active, not recruitingNCT06587191

Emapalumab Efficacy in Children With Primary Hemophagocytic Lymphohistiocytosis

Studying Acquired hemophagocytic lymphohistiocytosis associated with malignant disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Principal Investigator
Anna Scherbina, MD,Phd
Chief HSCT department at Federal Research Center for pediatric hematology, oncology and immunology
Enrollment
7 enrolled
Eligibility
18 years · All sexes
Timeline
20242024

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06587191 on ClinicalTrials.gov

Other trials for Acquired hemophagocytic lymphohistiocytosis associated with malignant disease

Additional recruiting or active studies for the same condition.

See all trials for Acquired hemophagocytic lymphohistiocytosis associated with malignant disease

← Back to all trials